Editas Medicine, Inc.
EDIT · NASDAQ
Financial statements
Annual and quarterly income, balance-sheet, cash-flow and key-statistics data.
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2022 FY | 19.71M | 13.38M | -225.95M | -220.43M | -3.21 |
| 2023 FY | 78.12M | 72.06M | -169.18M | -153.22M | -2.02 |
| 2024 FY | 32.31M | -166.93M | -251.15M | -237.09M | -2.88 |
| 2025 FY | 40.52M | 40.52M | -99.34M | -160.06M | -1.80 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2022 FY | 514.32M | 153.64M | 141.52M | 43.95M | 360.68M |
| 2023 FY | 499.15M | 150.06M | 123.65M | 48.54M | 349.10M |
| 2024 FY | 341.59M | 207.32M | 131.54M | 35.03M | 134.27M |
| 2025 FY | 186.53M | 159.25M | 146.65M | 76.71M | 27.29M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2022 FY | -177.35M | -4.12M | -181.47M | — | -62.00M |
| 2023 FY | -132.18M | -4.72M | -136.90M | — | -17.87M |
| 2024 FY | -210.28M | -8.83M | -219.11M | — | 7.89M |
| 2025 FY | -165.24M | -607.00K | -165.85M | — | 13.90M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2022 FY | 609.06M | 511.48M | — | — | — |
| 2023 FY | 769.53M | 694.42M | — | — | — |
| 2024 FY | 104.57M | 8.06M | — | — | — |
| 2025 FY | 181.93M | 111.99M | — | — | — |
| 2026-12-31 | — | — | — | — | — |
| 2027-12-31 | — | — | — | — | — |
| 2028-12-31 | — | — | — | — | — |
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 Q2 | 3.58M | -12.60M | -51.54M | -53.24M | -0.63 |
| 2025 Q3 | 7.54M | -12.23M | -24.55M | -25.12M | -0.28 |
| 2025 Q4 | 24.74M | 24.74M | -14.02M | -5.62M | -0.06 |
| 2026 Q1 | 2.83M | 2.35M | -25.00M | -24.98M | -0.26 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2025 Q2 | 210.58M | 191.39M | 138.54M | 21.14M | 19.19M |
| 2025 Q3 | 201.75M | 188.30M | 165.65M | 19.65M | 13.45M |
| 2025 Q4 | 186.53M | 159.25M | 146.65M | 76.71M | 27.29M |
| 2026 Q1 | 149.34M | 144.93M | 123.65M | 71.97M | 4.41M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2025 Q2 | -50.21M | — | -50.21M | — | -150.00K |
| 2025 Q3 | -30.84M | -433.00K | -31.28M | — | 25.90M |
| 2025 Q4 | -36.39M | -60.00K | -36.45M | — | -19.00M |
| 2026 Q1 | -23.06M | -92.00K | -23.15M | — | -23.00M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2025 Q2 | 185.71M | 68.30M | — | — | — |
| 2025 Q3 | 312.61M | 166.62M | — | — | — |
| 2025 Q4 | 181.93M | 111.99M | — | — | — |
| 2026 Q1 | 241.76M | 190.09M | — | — | — |
| 2026-06-30 | — | — | — | — | — |
| 2026-09-30 | — | — | — | — | — |
| 2026-12-31 | — | — | — | — | — |